Safety issues associated with using medication to treat overactive bladder

References

• Haylen BT, De Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.
   Google Scholar
• Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynaecol J. 2001;12:S66.
   Google Scholar
• National Collaborating Centre for Women's and Children's Health (UK). Urinary Incontinence in Women: The Management of Urinary Incontinence in Women. London: Royal College of Obstetricians and Gynaecologists (UK); 2013 Sep. (NICE Clinical Guidelines, No. 171.). Available from: https://www.ncbi.nlm.nih.gov/books/NBK247723/
   Google Scholar
• Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(suppl 21):11–14.
   PubMed Web of Science ®Google Scholar
• Fox C, Smith T, Maidment I, et al. Effect of medications with anticholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(5):604–615.
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study. BJU Int. 2001;87(9):760–766.
   PubMed Web of Science ®Google Scholar
• Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477–1483.
   PubMed Web of Science ®Google Scholar
• Kersten H, Wyller TB. Anticholinergic drug burden in older people’s brain–how well is it measured? Basic Clin Pharmacol Toxicol. 2014;114(2):151–159.
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Staskin DR, Kay GG, et al. Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012;29(4):259–273.
   PubMed Web of Science ®Google Scholar
• Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther. 2005;27(1):127–138.
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407.
   PubMed Web of Science ®Google Scholar
• Villalba-Moreno AM, Alfaro-Lara ER, Pérez-Guerrero MC, et al. Systematic review on the use of anticholinergic scales in poly pathological patients. Arch Gerontol Geriatr. 2016;62:1–8.
   PubMed Web of Science ®Google Scholar
• Tune LE, Egeli S. Acetylcholine and delirium. Dement Geriatr Cogn Disord. 1999;10(5):342–344.
   PubMed Web of Science ®Google Scholar
• Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64(9):1294–1300.
   PubMed Web of Science ®Google Scholar
• Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44(5):745–755.
   PubMed Web of Science ®Google Scholar
• Wagg A, Khullar V, Marschall‐Kehrel D, et al. Flexible‐dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double‐blind, placebo‐controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc. 2013;61(2):185–193.
   PubMed Web of Science ®Google Scholar
• Araklitis G, Thiagamoorthy G, Hunter J, et al. Anticholinergic prescription: are healthcare professionals the real burden? Int Urogynecol J. 2017;13:1–8.
   Google Scholar
• Wagg A, Nitti VW, Kelleher C, et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016;32(4):621–638.
   PubMed Web of Science ®Google Scholar
• Igawa Y, Schneider T, Yamazaki Y. Functional investigation of β-adrenoceptors in human isolated detrusor focusing on the novel selective β3-adrenoceptor agonist KUC-7322. Naunyn Schmiedebergs Arch Pharmacol. 2012;385(8):759–767.
   PubMed Web of Science ®Google Scholar
• D’ Agostino G, Maria Condino A, Calvi P. Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: direct evidence by [3H]-acetylcholine release experiments in the isolated detrusor. Eur J Pharmacol. 2015;758:115–122.
   PubMed Web of Science ®Google Scholar
• Mirabegron for treating symptoms of overactive bladder. Technology appraisal guidance [TA290]. National institute for health and care excellence. 2013. Available from: https://www.nice.org.uk/guidance/ta290
   Google Scholar
• Tao W, Xi D, Chen-Xi C. The role of mirabegron in overactive bladder: a systematic review and meta-analysis. Urol Int. 2014;93:326–337.
   PubMed Web of Science ®Google Scholar
• Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65:755–765.
   PubMed Web of Science ®Google Scholar
• Drug Safety Update. Mirabegron (Betmiga): risk of severe hypertension and associated cerebrovascular and cardiac events. 2015;9:1. . Available from: https://www.gov.uk/drug-safety-update715/mirabegron-betmiga-risk-of-severe-hypertension-andassociated-cerebrovascular-and-cardiac-events
   Google Scholar
• Chapple C, Amarenco G, Lopez Aramburu M, et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013;32:1116–1122.
   PubMed Web of Science ®Google Scholar
• Chapple C, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24:1447–1458.
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo J, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283–295.
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82:313–320.
   PubMed Web of Science ®Google Scholar
• Chapple C, Kaplan S, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296–305.
   PubMed Web of Science ®Google Scholar
• Rosa GM, Ferrero S, Nitti VW, et al. Cardiovascular safety of β 3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol. 2016;69(2):311–323.
   PubMed Web of Science ®Google Scholar
• Duthie JB, Vincent M, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Lib. 2011 Jan 1.
   Google Scholar
• Thiagamoorthy G, Cardozo L, Robinson D. Current and future pharmacotherapy for treating overactive bladder. Expert Opin Pharmacother. 2016;17(10):1317–1325.
   PubMed Web of Science ®Google Scholar
• Cui Y, Zhou X, Zong H, et al. The efficacy and safety of onabotulinumtoxin A in treating idiopathic OAB: a systematic review and meta‐analysis. Neurourol Urodyn. 2015;34(5):413–419.
   PubMed Web of Science ®Google Scholar
• Mohee A, Khan A, Harris N, et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111:106–113.
   PubMed Web of Science ®Google Scholar
• Sun Y, Luo D, Tang C, et al. The safety and efficiency of onabotulinumtoxin A for the treatment of overactive bladder: a systematic review and meta-analysis. Int Urol Nephrol. 2015;47(11):1779–1788.
   PubMed Web of Science ®Google Scholar
• Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology. 2005;66:94–98.
   PubMed Web of Science ®Google Scholar
• Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum a injection. J Urol. 2008;180:217–222.
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxin A for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184:2416–2422.
   PubMed Web of Science ®Google Scholar
• Kuo HC. Will suburothelial injection of a small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology. 2006;68:993–998.
   PubMed Web of Science ®Google Scholar
• Sievert K, Chapple C, Herschorn S, et al. Onabotulinumtoxin A 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. Int J Clin Pract. 2014;68:1246–1256.
   PubMed Web of Science ®Google Scholar
• Chohan N, Hilton P, Brown K, et al. Efficacy and duration of response to botulinum neurotoxin A (onabotulinum A) as a treatment for detrusor overactivity in women. Int Urogynecol J. 2015;26(11):1605–1612.
   PubMed Web of Science ®Google Scholar
• Khan S, Kessler T, Apostolidis A, et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type A injection. J Urol. 2009;181:1773–1778.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Ginsberg D, Sievert KD, et al. Durable efficacy and safety of long-term Onabotulinumtoxin A treatment in patients with overactive bladder syndrome: final results of a 3.5 year study. J Urol. 2016;196(3):791–800.
   PubMed Web of Science ®Google Scholar
• EMBARK Study Group, Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–2193.
   PubMed Web of Science ®Google Scholar
• Miotla P, Cartwright R, Futyma K, et al. Can botox improve night‐time overactive bladder symptoms in women? Neurourol Urodyn. 2017;36(3):648–652.
   PubMed Web of Science ®Google Scholar
• Miotla P, Cartwright R, Skorupska K, et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk? Int Urogynecol J. 2017;28(6):845–850.
   PubMed Web of Science ®Google Scholar
• Liao CH, Wang CC, Jiang YH. Intravesical onabotulinumtoxina injection for overactive bladder patients with frailty, medical comorbidities or prior lower urinary tract surgery. Toxins. 2016;8(4):91.
   PubMed Web of Science ®Google Scholar
• Eldred-Evans D, Sahai A. Medium-to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. Ther Adv Urol. 2017;9(1):3–10.
   PubMed Web of Science ®Google Scholar
• Jeffery S, Fynes M, Lee F, et al. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int. 2007;100:1302–1306.
   PubMed Web of Science ®Google Scholar
• Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol. 2010;58(6):919–926.
   PubMed Web of Science ®Google Scholar
• Pannek J, Göcking K, Bersch U. Long term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int. 2009;104:1246–1250.
   PubMed Web of Science ®Google Scholar
• Brin MF, Kirby RS, Slavotinek A, et al. Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiol Drug Saf. 2016;25(2):179–187.
   PubMed Web of Science ®Google Scholar
• Batra SC, Iosif LS. Progesterone receptors in the female urinary tract. J Urol. 1987;138:130–134.
   PubMed Web of Science ®Google Scholar
• Iosif C, Bekassy Z. Prevalence of genitourinary symptoms in the late menopause. Acta Obstet Gynaecol Scan. 1984;63:257–260.
   PubMed Web of Science ®Google Scholar
• Cardozo LD, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicenter study. Maturitas. 1993;18:47–53.
   PubMed Web of Science ®Google Scholar
• Tanidir Y, Ercan F, Tarcan T. Exogenous testosterone and estrogen affect bladder tissue contractility and histomorphology differently in rat ovariectomy model. J Sex Med. 2011;8:1626–1637.
   PubMed Web of Science ®Google Scholar
• Serati M, Salvatore S, Uccella S, et al. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Eur Urol. 2009;55:713–719.
   PubMed Web of Science ®Google Scholar
• Cody JD, Jacobs ML, Richardson K, et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;10:CD001405.
   PubMedGoogle Scholar
• Cardozo L, Lose G, McClish D, et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004 Oct 1; 83(10):892–897.
   PubMed Web of Science ®Google Scholar
• Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int. 2013 Dec;19(4):155–162.
   PubMedGoogle Scholar
• Nelken RS, Ozel BZ, Leegant AR, et al. Randomised trial of oestradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause. 2011;18:962–966.
   PubMed Web of Science ®Google Scholar
• Jiang F, Zhu L, Xu T, et al. Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women—a multicenter, randomized, open-label, controlled comparison study. Menopause. 2016;23(4):451–457.
   PubMed Web of Science ®Google Scholar
• Robinson D, Cardozo L, Milsom I, et al. Oestrogens and overactive bladder. Neurourol Urodyn. 2014;33(7):1086–1091.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Lib. 2016 Jan 1.
   Google Scholar
• Cancer research UK [Internet]. London:Cancer research UK. cited 2015 Dec 2. Available from: http://about-cancer.cancerresearchuk.org/about-cancer/breast-cancer/about
   Google Scholar
• The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606–616.
   PubMedGoogle Scholar
• Brown SB, Hankinson SE. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids. 2015 Jul;31(99):8–10.
   Web of Science ®Google Scholar
• Cuzick J. Is hormone replacement therapy safe for breast cancer patients? J Natl Cancer Inst. 2001;93:733–734.
   PubMedGoogle Scholar
• Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121–134.
   PubMed Web of Science ®Google Scholar
• Ponzone R, Biglia N, Jacomuzzi ME, et al. Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer. 2005;41(17):2673–2681.
   PubMed Web of Science ®Google Scholar
• Nilsson K, Heimerb G. Low-dose 17P-oestradiol during maintenance therapy – a pharmacokinetic and pharmacodynamic study. Maturitas. 1995;21:33–38.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause. 2002;9:179–187.
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Funk S, Nanavati N, et al. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002;99:556–562.
   PubMed Web of Science ®Google Scholar
• Diller M, SchüLer S, Buchholz S, et al. Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines. Maturitas. 2014;77:336–343.
   PubMed Web of Science ®Google Scholar
• Biglia N, Bounous VE, Sgro LG, et al. Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe hopes? Clin Breast Cancer. 2015;15(6):413–420.
   PubMed Web of Science ®Google Scholar
• O’Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 2001;93:754–762.
   PubMed Web of Science ®Google Scholar
• Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climateric. 2003;6:45–52.
   PubMed Web of Science ®Google Scholar
• Le Ray I, Dell’Aniello S, Bonnetain F, et al. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case–control study. Breast Cancer Res Treat. 2012;135(2):603–609.
   PubMed Web of Science ®Google Scholar
• Kendall A, Dowsett M, Fokerd E, et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17:584.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Committee opinion number 659. Obstet Gynecol. 2016;127:e93–6.
   PubMed Web of Science ®Google Scholar